A 62-year-old woman from Delhi presents with a 3-month history of bright red blood per rectum, tenesmus, and a palpable mass on digital rectal examination 7 cm from the anal verge. Colonoscopy confirms an ulcerated lesion; biopsy shows moderately differentiated adenocarcinoma. MRI pelvis shows invasion into the muscularis propria with involvement of internal sphincter; 2 out of 15 lymph nodes are positive. No distant metastases on staging CT. The patient is continent and has good sphincter function. What is the most appropriate surgical management?

Explanation

## Clinical Assessment This patient has a **mid-to-low rectal cancer** (7 cm from anal verge, T2N1M0, stage IIIA) with **intact sphincter function** and no contraindications to sphincter-preserving surgery. ### Rectal Cancer Anatomy & Surgical Strategy **Key Point:** The distance from the anal verge determines whether sphincter-preserving surgery is feasible. Tumors ≥5 cm from the anal verge with intact sphincters are candidates for anterior resection with TME. | Tumor Location | Distance from AV | Sphincter Status | Surgery of Choice | |---|---|---|---| | **Upper rectum** | >12 cm | Any | Anterior resection + TME | | **Mid rectum** | 7–12 cm | Intact | Anterior resection + TME | | **Mid rectum** | 7–12 cm | Involved/destroyed | APR | | **Low rectum** | <7 cm | Intact | Ultra-low AR + TME ± neoadjuvant RT | | **Low rectum** | <7 cm | Destroyed | APR | ### Why Low Anterior Resection with TME? 1. **Tumor location:** 7 cm from anal verge = mid-to-low rectum (within TME zone) 2. **Sphincter status:** Intact internal sphincter and good continence — sphincter-preserving surgery is appropriate 3. **Invasion depth:** T2 (muscularis propria) — does NOT mandate APR; sphincter invasion alone (without functional loss) does not preclude anterior resection 4. **Lymph node involvement:** N1 disease requires adequate mesorectal dissection; TME is the standard 5. **Neoadjuvant therapy:** With T2N1 disease, **neoadjuvant chemoradiation** (45–50 Gy + 5-FU) should be considered preoperatively to downstage and improve local control 6. **Anastomosis:** At 7 cm, a colorectal anastomosis is safe; a coloanal anastomosis is not needed **High-Yield:** **TME (Total Mesorectal Excision)** is the gold standard for ALL rectal cancers (within 15 cm of anal verge). It involves en bloc resection of the rectum and mesorectum (fat, vessels, lymph nodes) within the visceral peritoneal envelope. This reduces local recurrence from ~30% to <10%. **Clinical Pearl:** Neoadjuvant chemoradiation is indicated for **T3–T4 or node-positive rectal cancers** to improve local control and downstage tumors, potentially allowing sphincter preservation in borderline cases. This patient (T2N1) may benefit from neoadjuvant therapy. ### Why NOT the Other Options? - **APR (Abdominoperineal Resection):** Reserved for tumors <5 cm from anal verge OR when the sphincter is invaded/destroyed and continence cannot be preserved. This patient's sphincter is intact and functional; APR would unnecessarily sacrifice continence. - **Hartmann's procedure:** A staged approach (colostomy + rectal pouch) is used for acute obstruction or unstable patients. This patient is stable and does not have acute obstruction; primary anastomosis is safe. - **Local transanal excision:** Appropriate only for **T1N0M0 tumors** with favorable histology (well-differentiated, no lymphovascular invasion). This patient has T2N1 disease; transanal excision is inadequate and will not address regional nodes. ## Staging & Prognosis **Mnemonic: TNM — T2N1M0 = Stage IIIA** - T2: Invasion of muscularis propria (not beyond visceral peritoneum) - N1: 1–3 regional lymph nodes - M0: No distant metastases - **5-year survival:** ~65–70% with TME + adjuvant chemotherapy **Key Point:** Adjuvant 5-FU/LV ± oxaliplatin (FOLFOX) is standard for stage III rectal cancer. Neoadjuvant chemoradiation is increasingly used for T2N+ disease to improve local control.